Jaguar Health (JAGX) Stock Price, News & Analysis

Company Overview

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Key Stats

• Today's Range: $0.96 to $1.00
• 50-Day Range: $0.92 to $1.35
• 52-Week Range: $0.90 to $24.30
• Volume: 91,627 shs
• Average Volume: 731,951 shs
• Market Capitalization: $8.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Jaguar Health Stock Analysis - MarketRank™

Jaguar Health scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Jaguar Health.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jaguar Health are expected to decrease in the coming year, from ($0.78) to ($2.61) per share.

Price to Book Value per Share Ratio

Jaguar Health has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.31% of the float of Jaguar Health has been sold short.

Short Interest Ratio / Days to Cover

Jaguar Health has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jaguar Health has recently increased by 138.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jaguar Health does not currently pay a dividend.

Dividend Growth

Jaguar Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.31% of the float of Jaguar Health has been sold short.

Short Interest Ratio / Days to Cover

Jaguar Health has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jaguar Health has recently increased by 138.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.70

News Sentiment

Jaguar Health has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Jaguar Health this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for JAGX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Jaguar Health to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jaguar Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.01% of the stock of Jaguar Health is held by insiders.

Percentage Held by Institutions

Only 12.04% of the stock of Jaguar Health is held by institutions.

JAGX Stock Analysis - Frequently Asked Questions

How have JAGX shares performed this year?

Jaguar Health's stock was trading at $9.0840 at the beginning of the year. Since then, JAGX shares have decreased by 89.3% and is now trading at $0.9736.
View the best growth stocks for 2024 here.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) released its earnings results on Tuesday, August, 13th. The biotechnology company reported ($4.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by $2.84. The biotechnology company had revenue of $2.72 million for the quarter. Jaguar Health had a negative trailing twelve-month return on equity of 326.62% and a negative net margin of 360.13%.

When did Jaguar Health's stock split?

Jaguar Health shares reverse split on the morning of Thursday, May 23rd 2024. The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did Jaguar Health IPO?

Jaguar Health (JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp served as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Who are Jaguar Health's major shareholders?

Jaguar Health's top institutional shareholders include Virtu Financial LLC (0.28%).
View institutional ownership trends.

How do I buy shares of Jaguar Health?

Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jaguar Health investors own include Block (SQ), CrowdStrike (CRWD), Palantir Technologies (PLTR), NVIDIA (NVDA), Meta Platforms (META), Digital Turbine (APPS) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 8/13/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JAGX
• CUSIP: N/A
• CIK: 1585608
• Web: www.jaguaranimalhealth.com
• Phone: (415) 371-8300
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-41,300,000.00
• Net Margins: -360.13%
• Pretax Margin: -365.71%
• Return on Equity: -326.62%
• Return on Assets: -67.02%

Debt

• Debt-to-Equity Ratio: 1.65
• Current Ratio: 1.84
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $9.76 million
• Price / Sales: 0.92
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 9,240,000
• Free Float: 9,240,000
• Market Cap: $9.00 million
• Optionable: No Data
• Beta: 0.87